Helix B Surfacepeptide Reduces Sepsis-Induced Kidney Injury via PI3K/Akt Pathway.
Helix B-Surface peptide (HBSP) is the latest discovered erythropoietin analogue that can retain the activity of erythropoietin (EPO). EPO, which is widely used for treating renal anemia, has recently been proved to have protective effects on ischemia-reperfusion injury of brain, heart and kidney. The protective effects of EPO and HBSP on cardiac function were found in rats with myocardial ischemia. However, the effect of HBSP on sepsis-induced renal injury is still unclear. Establishment of rat kidney injury model and treated with HBSP and lipoposaccharide. Renal injury in rats was observed by HE staining and injury index score. Levels of serum creatinine (SCr), blood urea nitrogen (BUN) and Cystatin C (Cys C) were detected using fully automatic biochemical analyser, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-1β were detected by enzyme-linked immunosorbent assay (ELISA). Western blot (WB) analysis was performed to determine the role of HBSP in phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Acute kidney injury (AKI) appeared after modeling, however, HBSP alleviated the pathological conditions of the kidney injury. In addition, HBSP lowered kidney injury index score in the rats, and decreased the levels of SCr, BUN, Cys C, TNF-α, IL-6, and IL-1β, moreover, HBSP also showed the effect of activating PI3K/Akt pathway. HBSP alleviated lipoposaccharide-induced AKI and improved kidney function of the rats with sepsis. More importantly, the effects of HBSP on LPS-induced AKI were realized via activating PI3K/Akt pathway. The findings in the current study provide new insights into the therapeutic mechanism for treating the disease. This article is protected by copyright. All rights reserved.